Stock IMM IMMUTEP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Immutep Limited

Equities

IMM

AU000000IMM6

Market Closed - Australian S.E.
Other stock markets
 02:10:46 2024-04-30 am EDT 		5-day change 1st Jan Change
0.43 AUD -3.37% Intraday chart for Immutep Limited +21.13% +24.64%
Apr. 30 Canaccord Starts Immutep at Buy, Price Target is AU$1.00 MT
Apr. 24 Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck MT

Evolution of the average Target Price on Immutep Limited

Price target over the last 5 years

History of analyst recommendation changes

5228dd22793.Ct8koyMGfznxXIJdc06DKXn6VoxPElVXzjqRaPW6dsw.UqtXyFJ_GleLFs0QABi6TAi8Hr0MRQocnkmnMMTSAvtMlV3kemk4cMllww~049be60f19b53730b6c56d9def805233

Analyst Recommendations on Immutep Limited

Canaccord Starts Immutep at Buy, Price Target is AU$1.00 MT
Baird Initiates Immutep With Outperform Rating, $7 Price Target MT
Maxim Group Adjusts Price Target on Immutep to $10 From $8, Keeps Buy Rating MT
Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers CI
AIPAC final data as expected: Phase III supported with maintaining a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey) PU
O/W: IMMune to failure - Initiating coverage with a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey) PU
Immutep : Ladenburg Thalman - New Age Immune Regulator; Initiate with a Buy Rating and $8.30 Price Target PU
IMMUTEP : Ladenburg Thalmann Starts Immutep at Buy With $8.30 Price Target MT
Immutep : Maxim Group - Unlocking the Synergistic Benefits of Efti (LAG-3), the Next Checkpoint - Transferring Coverage with a Buy Rating and $8 PT PU
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.43 AUD
Average target price
0.978 AUD
Spread / Average Target
+127.44%
High Price Target
1.1 AUD
Spread / Highest target
+155.81%
Low Price Target
0.8 AUD
Spread / Lowest Target
+86.05%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Immutep Limited

Canaccord Genuity
Baird
Maxim
Ladenburg Thalmann

Ratings for Immutep Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IMM Stock
  4. Consensus Immutep Limited